P. A. Guerrero

This study identifies NKX6-2 as a driver of gastric differentiation in IPMNs, linking its expression to indolent biological potential and progression.

This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.

This study uses deep learning on plasma extracellular vesicle RNA to predict cancer subtypes, monitor treatment effects, and identify gene fusions and neoepitopes without tissue sampling.

This study integrates genomic and transcriptomic analysis of intraductal papillary mucinous neoplasms (IPMNs) to identify molecular features associated with progression to high-grade lesions and cancer.

This study shows that loss of Rnf43 accelerates Kras-driven pancreatic cancer and alters the tumor immune microenvironment by increasing lymphocytes and immune checkpoint expression.

The paper identifies CLPTM1L as a lipid scramblase essential for translocating glucosaminyl-phosphatidylinositol across the ER membrane during GPI biosynthesis.

This study reveals high intratumoral heterogeneity in pancreatic cancer cell lines and highlights issues with reproducibility and validity of preclinical models.

This study introduces CoDEX, a framework that links gene-cluster patterns with genetic vulnerabilities in PDAC, revealing subtype-specific dependencies and their impact on tumor phenotypes.

This study uses scRNA-seq on pancreatic cancer biopsies to characterize tumor-stromal heterogeneity and ligand-receptor interactions, showing its utility over patient-derived organoids for precision oncology.

This study uses single-cell RNA sequencing to analyze transcriptomic changes in pancreatic cancer precursors, revealing epithelial and microenvironmental heterogeneity during progression to cancer.